Cedar Mountain Advisors
SRPT icon

Cedar Mountain Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Cedar Mountain Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-24
Closed -$431 – 1229
2026
Q2 		$431 Hold
24
– – ﹤0.01% 1066
2026
Q1 		$522 Sell
24
-8
-25% -$155 ﹤0.01% 1006
2025
Q4 		$689 Buy
32
+8
+33% +$169 ﹤0.01% 566
2025
Q3 		$462 Buy
+24
New +$428 ﹤0.01% 612

Other funds holding SRPT

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Generali Investments CEE
Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Cedar Mountain Advisors's SRPT Position: Q3 2026 in Review

Cedar Mountain Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2026, closing a stake of 24 shares — an estimated $431 sold.

Cedar Mountain Advisors first reported a position in SRPT in Q3 2025 and held it in 4 quarters. The position peaked at $689 in Q4 2025. 92 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Cedar Mountain Advisors reported no remaining Sarepta Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Cedar Mountain Advisors sold 24 Sarepta Therapeutics shares in Q3 2026, an estimated $431.
  • Cedar Mountain Advisors first reported a position in Sarepta Therapeutics in Q3 2025 and held it in 4 quarters.
  • Cedar Mountain Advisors's Sarepta Therapeutics position peaked at $689 in Q4 2025.
  • 92 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.